Astellas Pharma Global Development, Inc.
astellas.comLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
200
Active
32
Phase 3
28
Total enrollment
123,920
Pipeline matrix
Showing 40 of 49 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| enfortumab vedotin | — | 11 | |||||
| Pembrolizumab | — | — | — | 17 | |||
| Oxaliplatin | — | — | — | 10 | |||
| zolbetuximab | — | — | 8 | ||||
| Capecitabine | — | — | — | 6 | |||
| fluorouracil | — | — | — | 5 | |||
| Gemcitabine | — | — | — | 5 | |||
| Leucovorin | — | — | — | 5 | |||
| Folinic acid | — | — | — | — | 4 | ||
| Irinotecan | — | — | — | 4 | |||
| ASP2138 | — | — | — | — | 3 | ||
| Setidegrasib | — | — | — | — | 3 | ||
| Docetaxel | — | — | — | 5 | |||
| Carboplatin | — | — | — | — | 4 | ||
| Cisplatin | — | — | — | — | 3 | ||
| 5-FU | — | — | — | — | 2 | ||
| Mirabegron | — | — | — | — | 5 | ||
| Roxadustat | — | — | — | — | 2 | ||
| 5-fluorouracil | — | — | — | — | 2 | ||
| Mitomycin C | — | — | — | — | — | 1 | |
| Tamoxifen | — | — | — | — | — | 1 | |
| Aromatase inhibitor | — | — | — | — | — | 1 | |
| liposomal irinotecan | — | — | — | — | — | 1 | |
| Fezolinetant | — | — | 11 | ||||
| Prednisone | — | — | — | — | 8 | ||
| Enzalutamide | — | — | 11 | ||||
| abiraterone acetate | — | — | — | — | — | 3 | |
| nab-paclitaxel | — | — | — | — | 2 | ||
| ASP5541 | — | — | — | — | 2 | ||
| gilteritinib | — | — | 17 | ||||
| Azacitidine | — | — | — | — | 3 | ||
| nivolumab | — | — | — | — | 2 | ||
| Prednisolone | — | — | — | — | — | 1 | |
| Adrenocorticotropic hormone | — | — | — | — | — | 1 | |
| ASP546C | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | — | 1 | |
| Leuprolide acetate | — | — | — | — | — | 1 | |
| ASP2998 | — | — | — | — | — | 1 | |
| Paclitaxel | — | — | — | 4 | |||
| Dexamethasone | — | — | — | — | 2 |
9 more active programs hidden
Next readouts
- 2022-09-09
- 2022-10-25
- 2022-12-22
- 2023-08-08
- 2025-02-25
- 2026-02-16
- 2026-06-30
- 2026-07-31
- 2026-07-31
- 2026-08-31
Top conditions
- Healthy Volunteers29
- Healthy Subjects20
- Pharmacokinetics of Isavuconazole18
- Advanced Solid Tumors10
- Prostate Cancer10
- Acute Myeloid Leukemia (AML)9
- Hot Flashes7
- Acute Myeloid Leukemia6
Frequently asked questions about Astellas Pharma Global Development, Inc.
- How many clinical trials does Astellas Pharma Global Development, Inc. have on ClinicalTrials.gov?
- Astellas Pharma Global Development, Inc. is listed as the lead sponsor on 200 clinical trials in ClinicalTrials.gov, 32 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Astellas Pharma Global Development, Inc.'s trials are in Phase 3?
- 28 of Astellas Pharma Global Development, Inc.'s trials are in Phase 3, spread across 49 active drug programs.
- What therapeutic areas does Astellas Pharma Global Development, Inc. focus on?
- Astellas Pharma Global Development, Inc.'s most-studied conditions on ClinicalTrials.gov are Healthy Volunteers, Healthy Subjects, Pharmacokinetics of Isavuconazole, Advanced Solid Tumors, Prostate Cancer.
- When are Astellas Pharma Global Development, Inc.'s next clinical trial readouts?
- Astellas Pharma Global Development, Inc. has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.”, expected around 2022-09-09.